Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Letters is Scopus-indexed (Q1, CiteScore 15.4), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier Ireland Ltd.
Checked against the index lists dated .
ISSN 0304-3835Verify ISSN ↗1872-7980Verify ISSN ↗
Publisher: Elsevier Ireland Ltd
Cost to publish: About US$4,960 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 31 / 428 | 92nd | Q1 |
| Cancer Research | 22 / 233 | 90th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1975–present, best quartile Q1, CiteScore 15.4.
Cancer Letters is Q1 in Oncology (rank 31 of 428) and Q1 in Cancer Research (rank 22 of 233), by CiteScore 2025.
Cancer Letters is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 15.4, which places it in quartile Q1 at the 92nd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 3.066, quartile Q1, with an H-index of 240.
The publisher lists an article processing charge of about US$4,960 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cancer Letters is published by Elsevier Ireland Ltd. Its print ISSN is 0304-3835 and its online ISSN is 1872-7980.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Cancer Letters has an h-index of 269 and a 2-year mean of 10.26 citations per paper (OpenAlex). Its Scopus CiteScore is 15.4, quartile Q1. On 2-year citations it ranks #18 of 424 Scopus journals in Oncology.
Cancer Letters published 598 papers in 2025; its busiest recent year was 2024 with 629. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2026), authors are most often from China (60.5%), United States (18.7%) and Australia (2.7%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 65 retracted papers are recorded (3.4 per 1,000 papers). The Problematic Paper Screener flags 3 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.